Skip to main content
Livermore
Livermore
ZHEN

Opaleye Management Inc.

SEC CIK
0001595855
Latest filing
Aug 14, 2026

The latest 13F from Opaleye Management Inc. covers Q2 2026 (filed Aug 14, 2026): 58 long positions worth $1.10B. The top 10 holdings make up 64.8% of the portfolio, and the largest is Liquidia Corp (LQDA) at 17.7%. Livermore has 25 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
13
Est. +$75.2M
Added
15
Est. +$81.5M
Reduced
13
Est. −$59.5M
Sold out
9
Est. −$38.4M

Top 5 holdings

Share of this quarter's portfolio value

  1. LQDALiquidia Corp
    17.7%$195.1MHistory
  2. ETONEton Pharmaceuticals, Inc.
    9.4%$103.5MHistory
  3. HROWHarrow, Inc.
    9.2%$101.9MHistory
  4. IRONDisc Medicine, Inc.
    5.7%$62.5MHistory
  5. URGNUroGen Pharma Ltd.
    4.8%$53.0MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. IRONDisc Medicine, Inc.
    +$31.7MAddedHistory
  2. IMMXImmix Biopharma, Inc.
    +$24.2MNewHistory
  3. MGTXMeiraGTx Holdings plc
    +$19.3MAddedHistory
  4. GLUEMonte Rosa Therapeutics, Inc.
    +$18.0MNewHistory
  5. REPLReplimune Group, Inc.
    +$15.3MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. IMMXImmix Biopharma, Inc.
    +2.19 pp0.0% → 2.2%History
  2. IRONDisc Medicine, Inc.
    +2.12 pp3.5% → 5.7%History
  3. MGTXMeiraGTx Holdings plc
    +1.92 pp2.4% → 4.3%History
  4. GLUEMonte Rosa Therapeutics, Inc.
    +1.63 pp0.0% → 1.6%History
  5. URGNUroGen Pharma Ltd.
    +1.41 pp3.4% → 4.8%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CATXPerspective Therapeutics, Inc.
    −$19.5MSold outHistory
  2. HROWHarrow, Inc.
    −$18.4MReducedHistory
  3. LQDALiquidia Corp
    −$7.77MReducedHistory
  4. SNWVSANUWAVE Health, Inc.
    −$6.75MReducedHistory
  5. JBIOJade Biosciences, Inc.
    −$6.28MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. HROWHarrow, Inc.
    −3.92 pp13.2% → 9.2%History
  2. RYTMRhythm Pharmaceuticals, Inc.
    −3.42 pp4.7% → 1.2%History
  3. CATXPerspective Therapeutics, Inc.
    −2.57 pp2.6% → 0.0%History
  4. SNWVSANUWAVE Health, Inc.
    −1.96 pp2.2% → 0.3%History
  5. ANNXAnnexon, Inc.
    −0.81 pp1.7% → 0.9%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.10B
+$345.0M (+45.4%) vs. prior quarter
Positions
58
+4 vs. prior quarter
Top 10 concentration
64.8%
Top 10 as share of value
Turnover
10.5%
Q2 2026, one quarter
Average holding period
11.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $1.10B (Q2 2026)

Q1 2021: $680.8MQ2 2021: $602.1MQ3 2021: $535.4MQ4 2021: $471.5MQ1 2022: $322.0MQ2 2022: $221.9MQ3 2022: $242.1MQ4 2022: $287.6MQ1 2023: $333.9MQ2 2023: $418.1MQ3 2023: $304.3MQ4 2023: $372.5MQ1 2024: $458.9MQ2 2024: $437.7MQ3 2024: $599.6MQ4 2024: $571.4MQ1 2025: $449.2MQ2 2025: $494.1MQ3 2025: $707.3MQ4 2025: $757.9MQ1 2026: $759.2MQ2 2026: $1.10B
Q1 2021Q2 2026
13F filings of Opaleye Management Inc. by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202658$1.10BLQDAETONHROWvs. Q1 2026SEC
Q1 2026May 15, 202654$759.2MHROWLQDAETONvs. Q4 2025SEC
Q4 2025Apr 13, 2026Amended54$757.9MHROWLQDAETONvs. Q3 2025SEC
Q3 2025Nov 14, 202543$707.3MHROWETONLQDAvs. Q2 2025SEC
Q2 2025Aug 15, 2025Amended41$494.1MHROWETONIMNMvs. Q1 2025SEC
Q1 2025May 15, 202545$449.2MHROWETONSNWVvs. Q4 2024SEC
Q4 2024Feb 14, 202539$571.4MHROWTGTXCDXSvs. Q3 2024SEC
Q3 2024Nov 14, 202444$599.6MHROWTGTXOCULvs. Q2 2024SEC
Q2 2024Aug 14, 202451$437.7MHROWTGTXOCULvs. Q1 2024SEC
Q1 2024May 29, 2024Amended52$458.9MOCULHROWTGTXvs. Q4 2023SEC
Q4 2023Feb 14, 202446$372.5MHROWTGTXSLRNvs. Q3 2023SEC
Q3 2023Nov 15, 202340$304.3MHROWSLRNOCULvs. Q2 2023SEC
Q2 2023Aug 14, 202347$418.1MSLRNHROWOCULvs. Q1 2023SEC
Q1 2023May 15, 202341$333.9MHROWOCULTELAvs. Q4 2022SEC
Q4 2022Feb 10, 202340$287.6MHROWTELARYTMvs. Q3 2022SEC
Q3 2022Nov 14, 202242$242.1MHROWOCULRYTMvs. Q2 2022SEC
Q2 2022Aug 15, 202247$221.9MHROWOCULCDXSvs. Q1 2022SEC
Q1 2022May 16, 202245$322.0MOCULCDXSCMRXvs. Q4 2021SEC
Q4 2021Feb 14, 202239$471.5MCDXSOCULCMRXvs. Q3 2021SEC
Q3 2021Nov 16, 202148$535.4MOCULCLDXCDXSvs. Q2 2021SEC
Q2 2021Aug 16, 202148$602.1MOCULCMRXCLDXvs. Q1 2021SEC
Q1 2021May 18, 202158$680.8MOCULCMRXTARA–SEC

13D and 13G filings

Companies where Opaleye Management Inc. reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

10 companies, largest stake first.

Companies where Opaleye Management Inc. owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
SLGLSol-Gel Technologies Ltd.13G/A15.41%500.0K shares−1.11 ppfrom 16.52%Aug 29, 20255 filingsMay 6, 2026SEC
ACOGAlpha Cognition Inc.13G/A14.22%3.10M shares+0.92 ppfrom 13.30%Oct 3, 20259 filingsJul 24, 2026SEC
GRCEGrace Therapeutics, Inc.13G13.07%2.75M sharesNewAug 7, 20261 filingAug 7, 2026SEC
IBIOiBio, Inc.13G/A7.60%750.0K shares–Apr 8, 20243 filingsFeb 14, 2025SEC
CDXSCodexis, Inc.13G/A7.47%6.79M shares−0.05 ppfrom 7.52%Jul 12, 20245 filingsMay 5, 2026SEC
RZLTRezolute, Inc.13G/A6.58%6.30M shares+1.28 ppfrom 5.30%Dec 19, 20252 filingsMay 11, 2026SEC
HROWHarrow, Inc.13G/A6.44%2.40M shares−1.17 ppfrom 7.61%Feb 12, 20216 filingsJul 31, 2026SEC
KTTAPasithea Therapeutics Corp.13G/A6.14%2.05M shares−3.85 ppfrom 9.99%Apr 8, 20262 filingsJul 31, 2026SEC
QTTBQ32 Bio Inc.13G/A5.49%931.0K shares−3.10 ppfrom 8.59%Feb 20, 20263 filingsJul 31, 2026SEC
GOSSGossamer Bio, Inc.13G5.10%24.9M sharesNewJul 29, 20261 filingJul 29, 2026SEC

Latest filings

86 filings on file made by Opaleye Management Inc. or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Opaleye Management Inc.
CompanyFiled (ET)FormStakeChangeEvent dateFiling
GRCEGrace Therapeutics, Inc.Aug 7, 20264:05 PM ET13G13.07%2.75M sharesNewAug 5, 2026SEC
KTTAPasithea Therapeutics Corp.Jul 31, 20264:05 PM ET13G/A6.14%2.05M shares−3.85 ppfrom 9.99%Jun 30, 2026SEC
HROWHarrow, Inc.Jul 31, 20264:05 PM ET13G/A6.44%2.40M shares−1.17 ppfrom 7.61%Jun 30, 2026SEC
SNWVSANUWAVE Health, Inc.Jul 31, 20264:05 PM ET13G/A3.60%309.9K shares−6.39 ppfrom 9.99%Below 5%Jun 30, 2026SEC
QTTBQ32 Bio Inc.Jul 31, 20264:05 PM ET13G/A5.49%931.0K shares−3.10 ppfrom 8.59%Jun 30, 2026SEC
GOSSGossamer Bio, Inc.Jul 29, 20264:05 PM ET13G5.10%24.9M sharesNewJul 22, 2026SEC
ACOGAlpha Cognition Inc.Jul 24, 20264:05 PM ET13G/A14.22%3.10M shares+0.92 ppfrom 13.30%Jul 23, 2026SEC
ACOGAlpha Cognition Inc.Jun 29, 20264:05 PM ET13G/A13.30%2.90M shares+1.27 ppfrom 12.03%Jun 26, 2026SEC
ACOGAlpha Cognition Inc.May 22, 20264:05 PM ET13G/A12.03%2.62M shares+0.26 ppfrom 11.77%May 21, 2026SEC
RZLTRezolute, Inc.May 11, 20264:25 PM ET13G/A6.58%6.30M shares+1.28 ppfrom 5.30%Mar 31, 2026SEC
KPTIKaryopharm Therapeutics Inc.May 11, 20264:23 PM ET13G/A2.67%619.1K shares−6.81 ppfrom 9.48%Below 5%Mar 31, 2026SEC
HROWHarrow, Inc.May 11, 20264:20 PM ET13G/A7.61%2.83M shares–Mar 31, 2026SEC
ACOGAlpha Cognition Inc.May 11, 20264:17 PM ET13G/A11.77%2.56M shares+0.77 ppfrom 11.00%Mar 31, 2026SEC
QTTBQ32 Bio Inc.May 6, 20264:05 PM ET13G/A8.59%1.26M shares−0.06 ppfrom 8.65%Mar 31, 2026SEC
SLGLSol-Gel Technologies Ltd.May 6, 20264:05 PM ET13G/A15.41%500.0K shares−1.11 ppfrom 16.52%Mar 31, 2026SEC
CDXSCodexis, Inc.May 5, 20264:05 PM ET13G/A7.47%6.79M shares−0.05 ppfrom 7.52%Mar 31, 2026SEC
SNWVSANUWAVE Health, Inc.May 4, 20264:05 PM ET13G/A9.99%858.6K shares–May 1, 2026SEC
KTTAPasithea Therapeutics Corp.Apr 8, 20268:25 PM ET13G9.99%2.49M sharesNewApr 1, 2026SEC
SLGLSol-Gel Technologies Ltd.Mar 23, 20266:52 PM ET13G/A16.52%460.3K shares+3.33 ppfrom 13.19%Feb 13, 2026SEC
ACOGAlpha Cognition Inc.Mar 4, 20264:05 PM ET13G/A11.00%2.39M shares+0.91 ppfrom 10.09%Mar 2, 2026SEC